FDA gives A-OK to Bothell company's cryo stem cell storage media
November 12, 2010 · Updated 3:40 PM
Bothell's BioLife Solutions Inc., a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues and organs, announced that its Master File for CryoStor cryopreservation media has been accepted by the United States Food and Drug Administration (FDA).
More than 100 development-stage cell therapy companies have evaluated or adopted HypoThermosol(R) and/or CryoStor in the production of novel cell-based products targeting a multitude of diseases and disorders such as cancer, heart failure, vision loss and neurologic disorders.
In addition, TriMark Publications, a global leader in market research and intelligence for biotechnology, health care and life sciences, forecasts the global market for stem-cell products and services to $104 billion by 2012.
PA Consulting Group, a global consulting firm with expertise in life sciences and health care, estimates the worldwide market for media to preserve cells, tissues and organs for research and clinical applications will grow from $200 million in 2007 to nearly $350 million by 2011.